OLK vs. GNMK, LMNX, VIVO, NTUS, BRKR, BIO, BIO.B, TXG, LAB, and CTKB
Should you be buying Olink Holding AB (publ) stock or one of its competitors? The main competitors of Olink Holding AB (publ) include GenMark Diagnostics (GNMK), Luminex (LMNX), Meridian Bioscience (VIVO), Natus Medical (NTUS), Bruker (BRKR), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), 10x Genomics (TXG), Standard BioTools (LAB), and Cytek Biosciences (CTKB).
Olink Holding AB (publ) (NASDAQ:OLK) and GenMark Diagnostics (NASDAQ:GNMK) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
Olink Holding AB (publ) has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, GenMark Diagnostics has a beta of 3.02, meaning that its stock price is 202% more volatile than the S&P 500.
Olink Holding AB (publ) has higher revenue and earnings than GenMark Diagnostics. Olink Holding AB (publ) is trading at a lower price-to-earnings ratio than GenMark Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Olink Holding AB (publ) had 4 more articles in the media than GenMark Diagnostics. MarketBeat recorded 4 mentions for Olink Holding AB (publ) and 0 mentions for GenMark Diagnostics. Olink Holding AB (publ)'s average media sentiment score of 1.70 beat GenMark Diagnostics' score of 0.00 indicating that Olink Holding AB (publ) is being referred to more favorably in the media.
Olink Holding AB (publ) presently has a consensus price target of $26.00, suggesting a potential upside of 8.29%. Given Olink Holding AB (publ)'s higher possible upside, equities analysts clearly believe Olink Holding AB (publ) is more favorable than GenMark Diagnostics.
30.2% of Olink Holding AB (publ) shares are owned by institutional investors. Comparatively, 96.9% of GenMark Diagnostics shares are owned by institutional investors. 5.2% of Olink Holding AB (publ) shares are owned by insiders. Comparatively, 3.3% of GenMark Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
GenMark Diagnostics has a net margin of -16.95% compared to Olink Holding AB (publ)'s net margin of -19.72%. Olink Holding AB (publ)'s return on equity of -7.07% beat GenMark Diagnostics' return on equity.
GenMark Diagnostics received 547 more outperform votes than Olink Holding AB (publ) when rated by MarketBeat users. Likewise, 67.11% of users gave GenMark Diagnostics an outperform vote while only 34.29% of users gave Olink Holding AB (publ) an outperform vote.
Summary
Olink Holding AB (publ) beats GenMark Diagnostics on 9 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding OLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olink Holding AB (publ) Competitors List
Related Companies and Tools
